EAACI Congress 2023
BackLong-Term Safety of Dupilumab in Patients with Moderate-to-Severe Asthma Who Completed the LIBERTY ASTHMA TRAVERSE Continuation Study
Friday 09 Jun, 14:27 PM -
14:39 PM CEST
Hall Y 03+04
ORAL Session